James Huang
James Huang's purchase track record
James Huang has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/29/2026 | CNTB | $372K | -10.8% | pending | — |
| 3/31/2026 | CNTB | $4.00M | -9.2% | -62.1% | +17.5% |
| 9/1/2021 | TCRT | $171K | -29.0% | -46.9% | -3.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Alaunos Therapeutics (TCRT) Moves in After-Hours Trading. Alaunos Therapeutics was listed among healthcare stocks moving in Friday's after-market session. The stock is currently trading near its support level of $1.97, with an RSI of 30.4 indicating it is in oversold territory. This price action occurs within a 52-week range of $0.97 to $4.59.
Transaction History
| CNTB | ▲ Buy | Open Market | 150,000 | $372K | 5/29/2026 | View on chart |
| CNTB | ▲ Buy | Open Market | 1,160,000 | $4.0M | 3/31/2026 | View on chart |
| TCRT | ▲ Buy | Grant | 80,000 | $0 | 6/22/2022 | View on chart |
| TCRT | ▲ Buy | Grant | 80,000 | $0 | 6/22/2022 | View on chart |
| TCRT | ▲ Buy | Open Market | 100,000 | $171K | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CNTB Misses Asthma Trial Goal as Oppenheimer Lowers Target
Connect Biopharma reported that its latest asthma trial did not meet the primary endpoint. The result may affect the progression of the drug program. Oppenheimer kept an Outperform rating but reduced its price target to $5, below the consensus $6.50. The stock is currently trading near its recent support level.
CNTB Misses Asthma Trial Goal as Oppenheimer Lowers Target. Connect Biopharma reported that its latest asthma trial did not meet the primary endpoint. The result may affect the progression of the drug program. Oppenheimer kept an Outperform rating but reduced its price target to $5, below the consensus $6.50. The stock is currently trading near its recent support level.